Boenning & Scattergood, Inc. Acadia Pharmaceuticals Inc Transaction History
Boenning & Scattergood, Inc.
- $622 Million
- Q4 2022
A detailed history of Boenning & Scattergood, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Boenning & Scattergood, Inc. holds 53,475 shares of ACAD stock, worth $989,822. This represents 0.21% of its overall portfolio holdings.
Number of Shares
53,475
Previous 30,260
76.72%
Holding current value
$989,822
Previous $495,000
161.62%
% of portfolio
0.21%
Previous 0.1%
Shares
14 transactions
Others Institutions Holding ACAD
# of Institutions
282Shares Held
158MCall Options Held
901KPut Options Held
314K-
Baker Bros. Advisors LP New York, NY42.9MShares$794 Million7.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.8MShares$256 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$254 Million3.36% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$223 Million0.0% of portfolio
-
State Street Corp Boston, MA5.97MShares$111 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...